Sickle cell disease (SCD) is a genetic blood disorder that causes significant multisystem morbidity and early mortality. For decades, blood transfusions and hydroxyurea were the main treatments available for SCD. Recently, several gene therapies have been FDA approved and multiple disease-modifying agents are under clinical development for SCD. Dr. Andemariam will discuss new and emerging treatment options for SCD.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 1515 W Cypress Creek Rd
Pricing
100% of listed courses are free
56 of 56 courses listed here are free.
Collected from the provider’s public pages
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Board review / self-assessment
- Credit · Up to 1.5 credits
- MOC · Up to 1.5 points
- Commercial Support
-
ReleasedOct 16, 2025
-
Last day to claim creditNov 1, 2026 3 weeks left
-
Kaplan Medical Education Beyond the Burden: Barriers and Unmet Needs in Sickle Cell Disease
-
Kaplan Medical Education Beyond the Conversation: Shared Decision Making and Care Coordination in Sickle Cell Disease
-
Kaplan Medical Education Trial Results Suggest a Growing Role for MRD Negativity to Guide Treatment
